EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Early diagnosis of brain metastases using cerebrospinal fluid cell‐free DNA‐based breakpoint motif and mutational features in lung cancer

Xueting Qin, Yujun Bai, Shizhen Zhou, Hongjin Shi, Xiaoli Liu, Song Wang, Xiaoying Wu, Jiaohui Pang, Xi Song, Xiaojun Fan, Qiuxiang Ou, Yang Xu iD und 5 weitere

Clinical and Translational Medicine · 2023

DOI: 10.1002/ctm2.1221 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Xueting Qin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Me…. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Lung Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Jinan Clinical Medicine Science and Technology Innovation Plan, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early diagnosis of brain metastases using cerebrospinal fluid cell-free DNA-based breakpoint motif and mutational features in lung cancerDear Editor, In this study, we developed a sensitive machine learning model with a remarkable capacity to predict brain metastases (BM) in lung cancer patients using the breakpoint motif (BPM) features in cerebrospinal fluid (CSF) circulating tumour DNA (ctDNA).We have also assessed the mutational profile in CSF ctDNA, revealing promising BM-related prognostic biomarkers in lung cancer patients.BM is frequently associated with a short life expectancy and a high mortality rate in lung cancer patients.1 Early detection and timely treatment help to ameliorate the disease severity for lung cancer BM (LCBM).Brain magnetic resonance imaging (MRI) is the preferred method to evaluate the number, size and location of BM, but it lacks clear guidance to indicate the appropriate timing for screening.Cancer treatment may also obscure contrast enhancement, making the BM diagnosis more challenging.2 Meanwhile, CSF cytology provides valuable information about the pathologic conditions of cells involved in the central nervous system (CNS) and its coverings but is not sensitive enough for definitive diagnosis and highly relies on the pathologist's experience.Therefore, exploring sensitive and accurate methods is essential for promoting the early detection of LCBM.Plasma cell-free DNA (cfDNA) analysis has been widely adopted for assessing genomic features of cancer patients, monitoring response to treatment, quantifying minimal residual disease, and examining therapy resistance.[3][4][5][6][7] Particularly, Guo et al. have leveraged the elastic-net logistic regression algorithm to integrate the 6 bp BPM feature in plasma cfDNA and successfully built a sensitive model for stage I lung adenocarcinoma detection.8 As CSF ctDNA has been gaining credibility for its high capability of detecting somatic genetic alterations in patients with CNS malignancies, 9 this study aims to develop a robust model for the sensitive detection of LCBM using genetic features derived from CSF ctDNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Free Nucleic AcidsLung NeoplasmsBrain NeoplasmsHumansEarly Detection of CancerMutation

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Department of Radiation Oncology, Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Chin…
  • Department of Radiation Oncology, Tai'an Central Hospital (Tai'an Central Hospital Affiliated to Qingdao University, Taishan Medical Care Center), Tai'an, China.
  • Department of Neurosurgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Shandong Cancer Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, China.
  • Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

ORCID-Profile: Yang Xu, Shuanghu Yuan

Förderung

  • Natural Science Foundation of China
  • Jinan Clinical Medicine Science and Technology Innovation Plan
  • National Natural Science Foundation of China

Zitieren

APA

Qin, X., Bai, Y., Zhou, S., Shi, H., Liu, X., Wang, S., Wu, X., Pang, J., Song, X., Fan, X., Ou, Q., Xu, Y., Bao, H., Li, L., Li, J., Shao, Y., & Yuan, S. (2023). Early diagnosis of brain metastases using cerebrospinal fluid cell‐free DNA‐based breakpoint motif and mutational features in lung cancer. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1221

Vancouver

Qin X, Bai Y, Zhou S, Shi H, Liu X, Wang S, et al. Early diagnosis of brain metastases using cerebrospinal fluid cell‐free DNA‐based breakpoint motif and mutational features in lung cancer. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1221

BibTeX
@article{Qin2023,
  author = {Qin, Xueting and Bai, Yujun and Zhou, Shizhen and Shi, Hongjin and Liu, Xiaoli and Wang, Song and Wu, Xiaoying and Pang, Jiaohui and Song, Xi and Fan, Xiaojun and Ou, Qiuxiang and Xu, Yang and Bao, Hua and Li, Li and Li, Jun and Shao, Yang and Yuan, Shuanghu},
  title = {Early diagnosis of brain metastases using cerebrospinal fluid cell‐free DNA‐based breakpoint motif and mutational features in lung cancer},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  doi = {10.1002/ctm2.1221}
}
Kostenlos starten →